FlandersBio on Twitter

Follow us on Twitter

Archive for November 2016 - News

Archive for November 2016 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

ABLYNX ACHIEVES FIRST MILESTONE AS PART OF COLLABORATION WITH NOVO NORDISK

30.11.2016

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has achieved an initial discovery milestone with a multi-specific Nanobody construct as part of its collaboration with Novo Nordisk, triggering a €1 million milestone payment to Ablynx. read more

Galapagos increases share capital through warrant exercises

30.11.2016

Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. read more

QAELUM – Belgian expert in medical quality monitoring & analysis – opens New York offices to kick off US business as part of its worldwide expansion

30.11.2016

After a 2M € internal capital round and appointing key experts, Qaelum NV – KULeuven-spinoff focussing on total quality monitoring in medical imaging – opens a new subsidiary in the United States. This milestone comes only months after strenthening Qaelum’s corporate & sales structure to support its fast global expansion. Working from the Qaelum offices in New York city, the sales team will target radiology and other departments in US and Canada hospitals. read more

Vijf Vlaamse hightech start-ups vervoegen het imec.istart-ondernemerschapsprogramma

29.11.2016

In het tweede kwartaal zijn opnieuw vijf beloftevolle hightech start-ups toegelaten tot het imec.istart-ondernemerschapsprogramma, één van de meest succesvolle ‘University Business Accelerator’-initiatieven ter wereld. Dankzij hun selectie kunnen de start-ups gedurende de volgende 18 maanden een beroep doen op financiële ondersteuning, professionele coaching en allerhande faciliteiten op maat van een startende onderneming. Een overzicht van de nieuwe lichting: read more

Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737

29.11.2016

Galapagos NV (Euronext & NASDAQ: GLPG) reports the initiation of a Phase 1 study in healthy volunteers with GLPG2737, a novel C2 corrector drug for cystic fibrosis. Initiation of the Phase 1 study triggers a $10 million milestone payment from AbbVie. read more

ONTOFORCE wins 1st prize in ‘Digital Health’ at healthcare innovation summit

29.11.2016

Last week, ONTOFORCE, a pioneer in semantic search technology that can link information from disparate data sources, has claimed the first spot in the ‘Digital Health’ category at the EIT Health Summit in Barcelona, for which it receives €25,000. In addition, ONTOFORCE came third in the public vote. EIT Health is a European institute that stimulates innovation and entrepreneurship in healthcare. read more

Biocartis Group NV: Disclosure of a transparency notification

28.11.2016

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 22 November 2016 (the 'Notification'), indicating that the shareholding of DHAM NV (which is controlled by KORYS NV, which is in turn controlled by Stichting Administratiekantoor Cozin) has decreased below the 3% notification threshold. read more

VIB scientists develop diagnostic tool for Familial Mediterranean Fever

25.11.2016

Researchers at VIB and Ghent University have developed a tool to diagnose Familial Mediterranean Fever (FMF). Particularly common among Mediterranean populations, this genetic disease is characterized by inflammation, fever and severe pain. Because of its complex diagnosis, patients often remain untreated for many years, which can eventually lead to kidney failure. In collaboration with Ghent University Hospital and Antwerp University Hospital, VIB and Ghent University are now planning clinical trials to further validate immunodiagnosis of FMF. The study is published in the leading scientific journal PNAS. read more

VIB-KU Leuven scientists discover neuron-producing stem cells in the membranes covering the brain

24.11.2016

In a cross-domain study directed by professor Peter Carmeliet (VIB – KU Leuven), researchers discovered unexpected cells in the protective membranes that enclose the brain, the so called meninges. These ‘neural progenitors’ – or stem cells that differentiate into different kinds of neurons – are produced during embryonic development. These findings show that the neural progenitors found in the meninges produce new neurons after birth – highlighting the importance of meningeal tissue as well as these cells’ potential in the development of new therapies for brain damage or neurodegeneration. A paper highlighting the results was published in the leading scientific journal Cell Stem Cell. read more

Galapagos selected for Stoxx Europe 600 Index

24.11.2016

Galapagos NV (Euronext & NASDAQ: GLPG) announces that Stoxx has selected Galapagos NV for inclusion in the Stoxx Europe 600 Index, effective 19 December 2016. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print